Zobrazeno 1 - 10
of 268
pro vyhledávání: '"Marc S. Raab"'
Autor:
Annika Werly, Mareike Hampel, Thomas Hielscher, Kosima Zuern, Sophia K. Schmidt, Alissa Visram, Marc S. Raab, Carsten Mueller-Tidow, Hartmut Goldschmidt, Elias K. Mai
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-4 (2024)
Externí odkaz:
https://doaj.org/article/e820784f1b954d469714c97ec2ab4e66
Autor:
Kosima Zuern, Thomas Hielscher, Annika Werly, Iris Breitkreutz, Sandra Sauer, Marc S. Raab, Carsten Müller-Tidow, Hartmut Goldschmidt, Elias K. Mai
Publikováno v:
Blood Cancer Journal, Vol 14, Iss 1, Pp 1-7 (2024)
Abstract Risk of progression of monoclonal gammopathy of undetermined significance (MGUS) into multiple myeloma and related plasma cell disorders can be determined by three major risk stratification models, namely Mayo2005, Sweden2014, and NCI2019. T
Externí odkaz:
https://doaj.org/article/8b59e6031f2a4f8abcea173fdef09306
Autor:
Joseph Kauer, Emma P. Freundt, Anita Schmitt, Niels Weinhold, Elias K. Mai, Carsten Müller-Tidow, Hartmut Goldschmidt, Marc S. Raab, Katharina Kriegsmann, Sandra Sauer
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-11 (2023)
Abstract Background While quadruplet induction therapies deepen responses in newly diagnosed multiple myeloma patients, their impact on peripheral blood stem cell (PBSC) collection remains incompletely understood. This analysis aims to evaluate the e
Externí odkaz:
https://doaj.org/article/0e45dc4a87824cea9db287d39be77c5b
Autor:
Marc S. Raab, Elena Zamagni, Salomon Manier, Paula Rodriguez‐Otero, Fredrik Schjesvold, Annemiek Broijl
Publikováno v:
eJHaem, Vol 4, Iss 4, Pp 1117-1131 (2023)
Abstract Overall outcomes for multiple myeloma have improved due to the availability of new therapies, but patients with relapsed/refractory multiple myeloma harbouring certain factors continue to pose a therapeutic challenge. These challenging featu
Externí odkaz:
https://doaj.org/article/8a6c23a03654471990d390e4f8fa5147
Autor:
Anja Seckinger, Hans Salwender, Hans Martin, Christof Scheid, Thomas Hielscher, Uta Bertsch, Manuela Hummel, Anna Jauch, Wolfgang Knauf, Martina Emde-Rajaratnam, Susanne Beck, Kai Neben, Jan Dührig, Walter Lindemann, Ingo G. H. Schmidt-Wolf, Mathias Hänel, Igor W. Blau, Katja Weisel, Niels Weinhold, Marc S. Raab, Hartmut Goldschmidt, Mimi Choon-Quinones, Dirk Hose
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 12, p 6431 (2024)
Based on the lack of differences in progression-free and overall survival after a median follow-up of 93 months in our HOVON-65/GMMG-HD4 trial (German part; n = 395) randomizing VAD induction (vincristin/adriamycin/dexamthasone)/tandem-transplantatio
Externí odkaz:
https://doaj.org/article/f202cde6902c4658b66eeee52a3753fd
Autor:
Lukas John, Alexandra M. Poos, Alexander Brobeil, Carolina Schinke, Stefanie Huhn, Nina Prokoph, Raphael Lutz, Barbara Wagner, Maurizio Zangari, Stephan M. Tirier, Jan-Philipp Mallm, Sabrina Schumacher, Dominik Vonficht, Llorenç Solé-Boldo, Sabine Quick, Simon Steiger, Moritz J. Przybilla, Katharina Bauer, Anja Baumann, Stefan Hemmer, Christoph Rehnitz, Christian Lückerath, Christos Sachpekidis, Gunhild Mechtersheimer, Uwe Haberkorn, Antonia Dimitrakopoulou-Strauss, Philipp Reichert, Bart Barlogie, Carsten Müller-Tidow, Hartmut Goldschmidt, Jens Hillengass, Leo Rasche, Simon F. Haas, Frits van Rhee, Karsten Rippe, Marc S. Raab, Sandra Sauer, Niels Weinhold
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-17 (2023)
Abstract In multiple myeloma spatial differences in the subclonal architecture, molecular signatures and composition of the microenvironment remain poorly characterized. To address this shortcoming, we perform multi-region sequencing on paired random
Externí odkaz:
https://doaj.org/article/1de2b57c538f40e487f459cc7a327e33
Autor:
Anna Luise Grab, Peter S. Kim, Lukas John, Kamlesh Bisht, Hongfang Wang, Anja Baumann, Helgi Van de Velde, Irene Sarkar, Debarati Shome, Philipp Reichert, Calin Manta, Stefanie Gryzik, Rogier M. Reijmers, Niels Weinhold, Marc S. Raab
Publikováno v:
Cells, Vol 13, Iss 10, p 879 (2024)
Current treatment strategies for multiple myeloma (MM) are highly effective, but most patients develop relapsed/refractory disease (RRMM). The anti-CD38/CD3xCD28 trispecific antibody SAR442257 targets CD38 and CD28 on MM cells and co-stimulates CD3 a
Externí odkaz:
https://doaj.org/article/8503b9abaeac4cfa9e1744711dde30b6
Autor:
Martina Emde-Rajaratnam, Susanne Beck, Vladimir Benes, Hans Salwender, Uta Bertsch, Christoph Scheid, Mathias Hänel, Katja Weisel, Thomas Hielscher, Marc S. Raab, Hartmut Goldschmidt, Anna Jauch, Ken Maes, Elke De Bruyne, Eline Menu, Kim De Veirman, Jérôme Moreaux, Karin Vanderkerken, Anja Seckinger, Dirk Hose
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
BackgroundImmunotherapeutic targets in multiple myeloma (MM) have variable expression height and are partly expressed in subfractions of patients only. With increasing numbers of available compounds, strategies for appropriate choice of targets (comb
Externí odkaz:
https://doaj.org/article/c65a30545a9545fdbf7aa6e375ae1aa6
Autor:
Elias K. Mai, Stefanie Huhn, Kaya Miah, Alexandra M. Poos, Christof Scheid, Katja C. Weisel, Uta Bertsch, Markus Munder, Oscar Berlanga, Dirk Hose, Anja Seckinger, Anna Jauch, Igor W. Blau, Mathias Hänel, Hans J. Salwender, Axel Benner, Marc S. Raab, Hartmut Goldschmidt, Niels Weinhold
Publikováno v:
Blood Cancer Journal, Vol 13, Iss 1, Pp 1-9 (2023)
Abstract Mass spectrometry (MS) is a promising tool for monitoring monoclonal protein in plasma cell dyscrasias. We included 480 transplant-eligible newly-diagnosed multiple myeloma (MM) patients from the GMMG-MM5 trial (EudraCT No. 2010-019173-16) a
Externí odkaz:
https://doaj.org/article/1275a2059f114b41a54bedff8ec0c75f
Autor:
Odai Darawshi, Barbara Muz, Shiri Gershon Naamat, Bellam Praveen, Mohamed Mahameed, Karin Goldberg, Priya Dipta, Miriam Shmuel, Francesca Forno, Shatha Boukeileh, Hadas Pahima, Julia Hermann, Marc S. Raab, Alexandra M. Poos, Niels Weinhold, Chaggai Rosenbluh, Moshe E. Gatt, Wilhelm Palm, Abdel Kareem Azab, Boaz Tirosh
Publikováno v:
Cell Death and Disease, Vol 13, Iss 11, Pp 1-12 (2022)
Abstract Multiple myeloma (MM) causes approximately 20% of deaths from blood cancers. Notwithstanding significant therapeutic progress, such as with proteasome inhibitors (PIs), MM remains incurable due to the development of resistance. mTORC1 is a k
Externí odkaz:
https://doaj.org/article/bd25967df6ec4e2f9bb9642f5cf33ff7